Introduction

The importance of the human papillomavirus (HPV) as an etiological factor in cervical cancer (CC) has been recognized since the 1980s (Muñoz et al. 1994). In developing regions, CC is the second most common type of cancer. In 2018, it caused approximately 311,000 deaths worldwide (WHO 2020). In America, 3.8 million cases were diagnosed in the same year, and about 1.3 million died (www.paho.org). According to GLOBOCAN Infections caused by the human immunodeficiency virus (HIV) and human papillomavirus (HPV) cause thousands of deaths worldwide each year. So far, there has been no consensus on whether there is a direct relationship between the incidence of neoplasms and the immunosuppression caused by HIV that could help understand if coinfection increases the likelihood of cervical cancer. The objective of the study was to identify the presence of genetic variants of HPV in a group of HIV-positive women and their possible association with cervical cancer. Cervical samples were taken from HIV-positive patients for cytological analysis to identify the HPV genotype by polymerase chain reaction (PCR) and sequencing. The most prevalent L1 capsid protein mutations in the HPV genotype were analyzed in silico. Various types of HPV were identified, both high-risk (HR) and low-risk (LR). The most prevalent genotype was HPV51. Analysis of the L1 gene sequences of HPV51 isolates showed nucleotide variations. Of the samples analyzed in Puebla, Mexico, HPV51 had the highest incidence (17.5%, 7/40). Different mutations, which could be used as population markers, were detected in this area, and they have not been reported in the L1 databases for HPV51 in Mexico. Genotypes 6, 14, 86, 87, 89, and 91, not detected or reported in samples from patients with HPV in Mexico, were also identified.

Data from the population analyzed suggest no direct relationship between HIV immunosuppression and cervical cancer, regardless of the high- or low-risk HPV genotype. Furthermore, it is possible to develop regional population markers for the detection of HPV based on the mutations that occur in the sequence of nucleotides analyzed.

Key words: cervical cancer, human immunodeficiency virus, human papillomavirus, polymorphism

FELIPE ORTIZ-GUTIÉRREZ1, LILIA SÁNCHEZ-MINUTTI2, JOSÉ F. MARTÍNEZ-HERRERA3, INDIANA D. TORRES-ESCOBAR4, ELIAS B. PEZZAT-SAID5, LUIS MÁRQUEZ-DOMÍNGUEZ5 and AMADO I. GRANDES-BLANCO1,*

1 Programa Institucional de Biomedicina Molecular, Escuela Nacional de Medicina y Homeopatía. Instituto Politécnico Nacional, CDMX, México
2 Laboratorio de Procesos Biotecnológicos, Universidad Politécnica de Tlaxcala, Tlaxcala, México
3 Oncología Médica y Neoplasias de Torax y Medicina Interna Centro de Cáncer Hospital ABC, CDMX, México
4 Facultad de Medicina, Benemérita Universidad Autónoma de Puebla, Puebla, México
5 Departamento de Investigación en Salud SSEP, Puebla, México
6 Laboratorio de Biología Molecular y Virología, Centro de Investigación Biomédica de Oriente, Instituto Mexicano del Seguro Social, Metepec, Puebla, México
7 Facultad de Ciencias de la Salud, Licenciatura en Nutrición, Universidad Autónoma de Tlaxcala, Tlaxcala, México

Submitted 11 September 2021, accepted 16 November 2021, published online 20 December 2021

Abstract

Identification of Genetic Variants of Human Papillomavirus in a Group of Mexican HIV/AIDS Patients and Their Possible Association with Cervical Cancer

* Corresponding author: A.I. Grandes-Blanco, Facultad de Ciencias de la Salud, Licenciatura en Nutrición, Universidad Autónoma de Tlaxcala, Tlaxcala, México; e-mail: isra2810@gmail.com
© 2021 Felipe Ortiz Gutiérrez et al. This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License (https://creativecommons.org/licenses/by-nc-nd/4.0/).
were performed by the hospital’s clinical analysis service. The HIV viral load measurement and the CD4+ lymphocyte count are done by considering the last CD4+ cells, one with >350 cells/mm³ and the other with <350 cells/mm³. This threshold was the main criterion for the initiation of antiretroviral therapy and was significantly associated with more rapid HPV clearance (Sabin and Phillips 2009; Kang and Cu-Uvin 2012).

**Biological material.** Two endocervical exfoliation samples were taken. One for cervical cytology analysis (a thin prep) and one for DNA extraction and PCR amplification.

**Cervical cytology.** A clean, non-lubricated vaginal mirror and an Ayre spatula were used to collect endocervical secretions. The smears were placed on previously labeled glass slides and fixed with 95% ethanol. After staining using the Papanicolaou method, the smears were analyzed in the Cytopathology Department of the Medical School of the Benemérita Universidad Autónoma de Puebla. Possible cellular abnormalities found by the thin prep were analyzed and classified according to the Bethesda classification system as Type I (negative), negative for intraepithelial lesion or malignancy; Type II (inflammatory process), reactive cellular changes associated with radiation, intrauterine contraceptive device, glandular cells status post hysterectomy, cellular changes consistent with viral activity, Trichomonas vaginalis, fungal organisms, etc.; Type III (LSIL): low-grade squamous intraepithelial lesions; Type IV (HSIL), high-grade squamous intraepithelial lesions (Nayar and Wilbur 2015).

**HPV Amplification Assays by Polymerase Chain Reaction.** For the collection of cervical samples and DNA extraction, the QIAamp Fast DNA tissue kit with dacron swabs and transport buffer (Qiagen) was used following the manufacturer’s instructions. For the amplification reaction, the QIAGEN Multiplex PCR kit was used following the manufacturer’s instructions, with the following general primers: MY09/11 and GP5+/GP6+. These primers amplify conserved sequences of the HPV L1 gene of both high and low-risk types. The primers for the actin gene were used as a internal control (Manos 1991; Qu et al. 1997). For the identification of HPV types in the amplified samples, the PCR products were sequenced with the dyeoxy method using an Abi Prism 310 Sequencer (Applied Biosystems) and the primer GP5+ in all sequencing reactions. The sequences obtained were aligned using the Basic Local Alignment Search Tool (BLAST) of the NCBI platform to determine the similarity of the regions of interest (Madden 2008).

**Nucleotide and amino acids sequence analysis.** The nucleotide and amino acid sequences of positive samples
were compared against GenBank using Blast. A multiple alignment of these sequences was performed (ClustalW Multiple Alignment v1.4) using BioEdit Sequence Alignment Editor version 7.0.9.0. (Hall 1999); For the analysis of nucleotides, the sequence MH777959.1 (Xu et al. 2019) was used as a reference. For the analysis of amino acid sequences, the sequence ARQ82736.1 was used (Oliveira et al. 2017). See the attached key resources table.

Homology modeling. The L1 structure of HPV51 was generated from amino acid sequences ARQ82736.1 in the I-TASSER platform (Roy et al. 2012; Yang and Zhang 2015). The preliminary sequence alignments were performed using the local meta-threading server of I-TASSER (Wu and Zhang 2007) to generate a list of templates for modeling (i.e., 3IYJ, 3OFL, 2R5K, and 1DZL). In addition to the sequence alignment, I-TASSER uses the TM-align structural alignment program to match the first I-TASSER model to all structures in the Protein Data Bank (PDB) library. For this monomer, the PDB codes used were 3IYJ, 1DZL, 2R5I, and 2R5K. The model validation outcome on the same website gave no hints of bad/unusual geometrical features. The visualization was performed using the program PyMOL (TM) 1.7.4.5 Molecular Graphics System, Version 2.0 Schrödinger, LLC.

Statistical analysis. Descriptive statistics were used for quantitative and categorical variables. The Pearson’s chi-squared test was used to check whether the prevalence of HPV infection increased with age or the presence of certain genotypes. The age of the patients was stratified into groups of < 45 years, 45–54 years, and > 54 years (Lazcano-Ponce et al. 2001; Tharcisse et al. 2020). The interaction between high-risk genotypes in each group of patients was also analyzed. Spearman’s Rho or Pearson’s tests were used to assess the correlation between the variables of viral load, CD4+ cell count, and low and high-risk subtypes of HPV. The statistical analysis was performed using IBM® SPSS® Statistics version 25.0. See the attached key resources table.

Results

Presence of HIV and immunological status of the patient. Clinical features. The analysis of the patients’ clinical history showed they had been infected with HIV for an average of 4.6 years after AIDS diagnosis and had been under antiretroviral treatment for an average of 3.46 years. Table I describes the age and the last measurement of CD4+ cells.

HPV prevalence. Amplification assays showed that 77.5% (31/40) of the study population were positive for some HPV type, while 22.5% (9/40) were negative. The following types of HR-HPV were found in 37.5%

| Patient age | HIV viral load (copies/ml) | CD4+ (cell/ml) | Pap cytology | HPV type |
|------------|--------------------------|----------------|--------------|----------|
|            |                          |                |              |          |
|            | Group I                  |                |              |          |
| 45         | < 50                     | 744            | I and II     | 90 (LR)  |
| 30         | < 50                     | 726            | I and II     | ND       |
| 23         | 5,840                    | 655            | I            | 11 (LR)  |
| 30         | < 50                     | 602            | I and II     | 97 (LR)  |
| 17         | 90,800                   | 580            | I and II     | 51 (HR)  |
| 42         | < 50                     | 521            | I            | ND       |
| 44         | < 50                     | 506            | I            | 66 (HR)  |
| 50         | 400                      | 503            | I and II     | 16 (HR)  |
| 38         | < 50                     | 458            | I            | 16 (HR)  |
| 27         | < 50                     | 481            | I and II     | 51 (HR)  |
| 37         | < 50                     | 410            | IV           | 51 (HR)  |
| 42         | < 50                     | 405            | I            | 11 (LR)  |
| 60         | 57                       | 388            | I            | 58 (HR)  |
| 29         | < 50                     | 380            | I and II     | 70 (LR)  |
| 31         | 4,940                    | 364            | I and II     | ND       |
| Group II   |                          |                |              |          |
| 35         | < 50                     | 317            | I and II     | ND       |
| 35         | < 50                     | 294            | IV           | ND       |
| 24         | 1,170                    | 282            | I and II     | ND       |
| 30         | < 50                     | 280            | III          | 54 (LR)  |
| 42         | < 50                     | 258            | I and II     | 102 (LR) |
| 49         | < 50                     | 255            | I and II     | 6 (LR)   |
| 35         | < 50                     | 208            | I            | 84 (LR)  |
| 32         | 369                      | 180            | I            | 51 (HR)  |
| 36         | 13,900                   | 175            | I and II     | 51 (HR)  |
| 37         | < 50                     | 161            | III          | 81 (LR)  |
| 28         | 67                       | 160            | I and II     | ND       |
| 24         | 74,620                   | 146            | I and II     | ND       |
| 51         | < 50                     | 132            | III          | 51 (HR)  |
| 37         | 73                       | 127            | IV           | 81 (LR)  |
| 48         | 5560                     | 104            | I and II     | 6 (LR)   |
| 43         | < 50                     | 103            | I and II     | 86 (LR)  |
| 37         | ND                       | 102            | I            | 56 (HR)  |
| 31         | < 50                     | 76             | III          | 52 (HR)  |
| 23         | > 100,000                | 70             | I and II     | 6 (LR)   |
| 34         | 822                      | 65             | III          | 58 (HR)  |
| 63         | 451                      | 63             | I and II     | ND       |
| 44         | 5,140                    | 60             | I and II     | 51 (HR)  |
| 25         | 95200                    | 30             | I and II     | 81 (LR)  |
| 41         | ND                       | 22             | III          | 33 (HR)  |
| 31         | > 100,000                | 16             | I and II     | 70 (LR)  |

1 – Pap cytology results according to the Bethesda classification system (2014 update) (Nayar 2015), see experimental procedures
2 – HPV type (HR – High Risk, LR – Low Risk, ND – not determined)
3 – CD4+ cell count results were classified into two groups, Group 1: > 350 cells/mm³ and Group 2: < 350 cells/mm³
(15/40) of the samples: 16, 33, 51, 52, 56, 58 and 66. The most frequent types were HPV 51 (17.5%, 7/40), 16 and 58 (both 5%, 2/40), 33, 52, 56 and 66 (each with 2.5%, 1/40). The following LR-HPV types were found in 40% of the samples: 6, 11, 54, 70, 81, 84, 86, 90, 97 and 102. The most frequent types were HPV 6 and 81 (both 7.5%, 3/40), followed by 11 and 70 (both 5%, 2/40), 54, 84, 86, 90, 97 and 102 (2.5% each, 1/40) (Table I, Fig. 1 and 2).

**Pap cytology, HPV and CD4+ lymphocytes status.** As can be seen in Table I and Fig. 2, nine (22.5%) patients presented some type of high or low grade cervical intraepithelial neoplasia, five were positive for some type of HPV-HR (33, 51, and 52), four were positive for some type of HPV-LR (54 and 81), and in only one patient with HGSIL the associated type of HPV could not be identified. Thus, no relationship was found between the type of HPV, its risk level, and the age of the patients (<45, 45–55, and ≥55 years) (Fig. 2).

As mentioned, HIV-positive patients were classified into two groups based on the number of CD4+ cells, one with >350 cells/mm³ and the other with <350 cells/mm³. It was found that 15 patients out of 40 (37.5%) had CD4+ cell counts >350 cells/mm³, while 25/40 (62.5%) had <350 cells/mm³ (Table I). According to the CDC classification system (CD4+ ≥ 500; CD4+ 200–499; CD4+ < to 200), and the presence of LR and HR-HPV genotypes was evaluated. According to Spearman’s test, there was no relationship between the prevalence of HPV subtypes and the CD4+ cell count (Kamps et al. 1994).

**HPV51 Nucleotide sequence analysis.** A multiple alignments of the identified HPV sequences was performed (Fig. 3). Several nucleotide substitutions could be observed in the primary sequence of the L1 protein from clinical samples. The analyzed sequences were translated, and the polymorphisms were identified through multiple alignments (Fig. 4).

**Structural analysis of the polymorphisms of HPV51.** There are reports of crystallized structures in the L1 region of different HPV types such as 16 and 18, but they had not been reported for HPV51. The L1 monomer of HPV51 was used to check whether the mutations found in patient samples in the present study corresponded to previously reported mutations (Bishop et al. 2007) in HPV16. The results showed that
Fig. 3. Comparison of nucleotide sequences of the L1 gene of HPV51 from clinical samples. The figure shows nucleotide sequences of seven HPV51-positive clinical isolates. The reference sequence is at the top. The nucleotides from the clinical samples that were homologous to the reference sequence are shown as points. Capital letters indicate differences concerning the reference sequence. Sequence alignment was performed using ClustalW multiple alignment software v1.4.

Fig. 4. Comparison of amino acid sequences of the L1 gene of HPV51 from clinical samples. The figure shows amino acids sequences of seven HPV51-positive clinical isolates. The reference sequence is at the top. The amino acids from the clinical samples that were homologous to the reference sequence are shown as points. Capital letters indicate differences with respect to the reference sequence. Sequence alignment was performed using ClustalW multiple alignment software v1.4.
Discussion

Cervical cancer is the third most common cancer affecting women in Mexico. The human papillomavirus is a factor associated with the development of this type of cancer. Furthermore, it has been reported that HIV-positive women have a higher prevalence of HPV and cervical cancer than HIV-negative women (Palefsky 2009). An HPV prevalence of 77.5% was found in the present study, which is very similar to what has been reported in other studies carried out in Mexico (Peralta-Rodríguez et al. 2012; Salcedo et al. 2014) and other countries (69–97.2%) (Sahasrabuddhe et al. 2007; Singh et al. 2009). The most common types of HPV in HIV-positive women in African countries such as Kenya and Togo have been reported to be: 16 (4.5%), 18 (3.1 to 8.6%), and 58 (3.6%) (Clifford et al. 2006; Menon et al. 2016; Nyasenu et al. 2019). Other authors have found that HPV types 52 (37.2%) (Clifford et al. 2006; Sahasrabuddhe et al. 2007; Menon et al. 2016; Abel et al. 2019; Nyasenu et al. 2019) and 45 (24.6%) (Desruisseau et al. 2009) have a higher prevalence. Moreover, it was found that HIV patients have a high prevalence (46.7–90.3%) of oncogenic HPV types (Sahasrabuddhe et al. 2007; Desruisseau et al. 2009; Menon et al. 2016; Vykandondera et al. 2019).

Several studies have long determined that the most common HPV types found in Mexico are HPV16, 18, 31 and 33 (Lazcano-Ponce et al. 2001; López Rivera et al. 2012; Aguilar-Lemarroy et al. 2015; Salcedo et al. 2015; Ortega-Cervantes et al. 2016). However, other genotypes have been detected with high frequency in some regions of Mexico. For example, HPV-31 is the most common type in cities such as Guanajuato and San Luis Potosí (López-Revilla et al. 2008), while genotype 58 is the most frequent in Yucatan (Canche et al. 2010). HPV has been found with a prevalence of 77.5% in Mexico, of which 37.5% corresponds to HR-HPV and 40% to LR-HPV types. Interestingly, the presence of uncommon HPV types has been identified in HIV-positive women such as types 54, 56, 70, 84, 86, 90, 97, and 102, both high and low risk (Table I) (Lazcano-Ponce et al. 2001; Montoya-Fuentes et al. 2001; López-Revilla et al. 2008; Salcedo et al. 2015). The present study found a high prevalence of HPV51 (17.5%) with various grades of the lesion (10% with grade I and II lesions; 2.5% in high- and low-grade intraepithelial neoplasia). The prevalence of HPV51 was thus three times higher than that of HPV16 and seven times higher than that of HPV33. It is consistent with the results of recent studies, which have also found a high prevalence of HPV51 in Mexico (Gallegos-Bolaños et al. 2017; Jácome-Galarza et al. 2017; Campos et al. 2019) and other countries such as Turkey (Gultekin et al. 2018), Greece (Argyri et al. 2018), Italy (Lillo et al. 2001), Tanzania (Mayaud et al. 2001), Kenya (Ferré et al. 2019; Omire et al. 2020) and Canada (de Pokomandy et al. 2018).

The present study results do not show an association between HPV types and the grade of the lesion. The variability in viral prevalence between studies may be due to the geographic location of the studied populations since it has been proposed that HPV types are differentially distributed among different populations and geographic locations (Yamada et al. 2008). As indicated above, there are different types of HPV in Mexico, and it is important to define the geographical distribution of these genotypes among the different regions of the country. A study on the phylogenetic classification of Alphapapillomavirus, including alpha-5 (HPV26, 51, 69, 82), determined that each genotype has an independent evolutionary history, that some regions of the capsid (L1) are more stable than others, and that certain variants are geographically related. Thus, it is important to determine specific polymorphisms (SNP’s) and their geographical dispersion (Chen et al. 2018). Different mutations in the structure of the HPV16 L1 pentamer have been reported (Rodrigues et al. 2018) to affect the loops containing the epitopes recognized by neutralizing antibodies. These mutations also affect the conformation and composition of the epitopes and the antigenicity of the viral surface.

Since the crystallized structure of the L1 region of HPV51 has not been reported before, a monomer was generated by homology to check if the mutations found in the patient samples corresponded to mutations reported before (Bishop et al. 2007). Fig. 5 shows the three-dimensional model of these mutations (the I21L, E26R,
I52L, V71G, and F72I mutations are highlighted). The mutations do not structurally alter the monomer, nor are they located in the regions recognized by neutralizing antibodies. Thus, they could be used as population markers, given that these mutations have not been reported in the L1 databases for HPV51 in Mexico. Finally, there is clinical evidence that the CD4+ T-cell dependent response is effective in controlling HIV infection or replication, and it has been suggested that a greater number of CD4+ T-cells could help control HPV infection in HIV-positive patients (Montoya Guarin et al. 2006; Hanisch et al. 2013; Chambuso et al. 2020). The results of the present study do not suggest a similar role for the CD4+ cells in controlling high or low-risk HPV infection, the number of CD4+ cells, or the type and frequency of neoplastic cervical lesions, which is consistent with the results of other studies (Sopracordevole et al. 1996; Cardillo et al. 2001). It was possible to identify a high prevalence of HPV-51 with nucleotide variations that could be used to characterize the viral polymorphism present in this specific population group.

ORCID
Amado Israel Grandes https://orcid.org/0000-0002-1120-1794

Conflict of interest
The authors do not report any financial or personal connections with other persons or organizations, which might negatively affect the contents of this publication and/or claim authorship rights to this publication.

Literature
Abel S, Najioilah F, Volumién JL, Accrombessi L, Carles G, Catherine D, Chiappetta D, Clavel C, Codjo-Sodokine A, El Guedj M, et al.; for HP2V study group. High prevalence of human papillomavirus infection in HIV-infected women living in French Antilles and French Guiana. PLoS One. 2019 Sep 4;14(9): e0221334. https://doi.org/10.1371/journal.pone.0221334

Aguilar-Lemarroy A, Vallejo-Ruíz V, Cortés-Gutiérrez EL, Salgado-Bernabé ME, Ramos-González NP, Ortega-Cervantes L, Arias-Flores R, Medina-Díaz IM, Hernández-Garza F, Santos-López G, et al.; INSS Research Network on HPV. Human papillomavirus infections in Mexican women with normal cytology, Lázaro G, et al.; Arias-Flores R, Medina-Díaz IM, Hernández-Garza F, Santos-López G, de Borja PE, Horta-Castillo ME, Villanueva FF, Ramos-González NP, Ortega-Cervantes L, Duque D; 2019 Jan 22.

Argyri E, Tsimplaki E, Papatheodorou D, Daskalopoulou D, Panotopoulou E. Recent trends in HPV infection and type distribution in Greece. Anticancer Res. 2018 May;38(5):3079–3084. https://doi.org/10.21873/anticancerres.12565

Bishop B, Dasgupta J, Klein M, Garcea RL, Christensen ND, Zhao R, Chen XS. Crystal structures of four types of human papillomavirus L1 capsid proteins: understanding the specificity of neutralizing monoclonal antibodies. J Biol Chem. 2007 Oct;282(43): 31803–31811. https://doi.org/10.1074/jbc.M706380200

Bruni L, Albero G, Serrano B, Mena M, Gómez D, Muñoz J, Bosch FX, de Sanjosé S. Human papillomavirus and related diseases in the World. Summary Report. Barcelona (Spain): ICO/IARC Information Centre on HPV and Cancer (HPV Information Centre); 2019 Jan 22.

Campos RG, Malacara Rosas A, Gutiérrez Santillán E, Delgado Gutiérrez M, Torres Orozco RE, García Martínez ED, Torres Bernal LF, Rosas Cabral A. Unusual prevalence of high-risk genotypes of human papillomavirus in a group of women with neoplastic lesions and cervical cancer from Central Mexico. PLoS One. 2019 Apr 18;14(4):e0215222. https://doi.org/10.1371/journal.pone.0215222

Canche JC, López IR, Suárez NG, Acosta GC, Conde-Ferréz I, Cetina TC, Losa MBG. High prevalence and low E6 genetic variability of human papillomavirus 58 in women with cervical cancer and precursor lesions in Southeast Mexico. Mem Inst Oswaldo Cruz. 2010 Mar;105(2):144–148. https://doi.org/10.1590/S0074-02762010000200006

Cardillo M, Hagan R, Abadi J, Abadi MA. CD4 T-cell count, viral load, and squamous intraepithelial lesions in women infected with the human immunodeficiency virus. Cancer. 2001 Apr 25;93(2):111–114. https://doi.org/10.1002/cncr.9016

Chambuso R, Kamesar R, Kaembo E, Murahwa AT, Abdallah MOE, De Sousa M, Denny I, Williamson AL, Gray CM. Age, absolute CD4 count, and CD4 percentage in relation to HPV infection and the stage of cervical disease in HIV-1-positive women. Medicine (Baltimore). 2020;99(9):e19273. https://doi.org/10.1097/MD.0000000000019273

Chen Z, Schifman M, Herrero R, DeSalle R, Anastos K, Segondy M, Sahasrabuddhe VV, Gravitt PE, Hsing AW, Chan PKS, et al. Classification and evolution of human papillomavirus genome variants: Alpha-5 (HPV26, 51, 69, 82), Alpha-6 (HPV53, 56, 66), Alpha-11 (HPV34, 73), Alpha-13 (HPV54) and Alpha-3 (HPV61). Virology. 2018 Mar;516:86–101. https://doi.org/10.1016/j.virology.2018.01.002

Clifford GM, Gonçalves MAG, Franchecchi S; HPV and HIV Study Group. Human papillomavirus types among women infected with HIV: a meta-analysis. AIDS. 2006 Nov 28;20(18):2337–2344. https://doi.org/10.1097/01.aids.0000253361.63578.14

Clifford GM, Polese J, Rickenbach M, Dal Maso L, Keiser O, Koller A, Rapiti E, Levi F, Jundt G, Fisch T, et al.; Swiss HIV Cohort. Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy. J Natl Cancer Inst. 2005 Mar 16;97(6):425–432. https://doi.org/10.1093/jnci/dji072

de Pokomandy A, de Pokomandy A, Lessard B, Mayrand MH, Charest L, Marcus V, Rodrigues-Coutlée S, Coutlée F. The role of human papillomavirus and cervical cancer in a female sex workers in Togo: a national cross-sectional survey. Clin Microbiol Infect. 2019 Dec;25(12):1560.e1–1560.e7. https://doi.org/10.1016/j.cmi.2019.07.029

Desruisseau AJ, Schmidt-Grimminger D, Welty E. Epidemiology of HPV in HIV-positive and HIV-negative fertile women in Cameroon, West Africa. Infect Dis Obstet Gynecol. 2009;2009:1–6. https://doi.org/10.1155/2009/810596

Egawa N, Doorbar J. The low-risk papillomaviruses. Virus Res. 2017 Mar;231:119–127. https://doi.org/10.1016/j.virusres.2016.12.017

Ferre VM, Ekouevi DK, Gbeasor-Komlanvi FA, Collin G, Le Hingrat Q, Tchounga B, Salou M, Descamps D, Charpentier C, Dagnara AC. Prevalence of human papillomavirus, human immunodeficiency virus and other sexually transmitted infections among female sex workers in Togo: a national cross-sectional survey. Clin Microbiol Infect. 2019 Dec;25(12):1560.e1–1560.e7. https://doi.org/10.1016/j.cmi.2019.04.015
The role of HPV

Association of HIV viral load and CD4 cell

Human

Prevalence of

noma. Infect Agent Cancer. 2008 Dec;3(1):3.

López-Revilla R, Martínez-Contreras LA, Sánchez-Garza M.
https://doi.org/10.1155/2012/384758

from Mexico City. Infect Dis Obstet Gynecol. 2012;2012:1–4.

Sánchez Monroy V.

https://doi.org/10.1086/322856

antiretroviral therapy. J Infect Dis. 2001 Sep;184(5):547–551.

Lillo FB, Ferrari D, Veglia F, Origoni M, Grasso MA, Lodini S,

IJC1071>3.0.CO;2-M

cytology. Int J Cancer. 2001 Feb 1;91(3):412–420.

https://doi.org/10.1111/j.1468-1293.2011.00979.x

Lazcano-Ponce E, Herrero R, Muñoz N, Cruz A, Shah KV,

Alonso P, Hernandez P, Salmeron J, Hernandez M. Epidemiology

of HPV infection among Mexican women. J Infect Dis. 2001;193(3):412–420.

https://doi.org/10.1093/infdis/i384758

López-Revilla R, Martínez-Contreras LA, Sánchez-Garza M.
Prevalence of high-risk human papillomavirus types in Mexican women with cervical intraepithelial neoplasia and invasive carcinoma. Infect Agent Cancer. 2008 Dec;3(1):3.

https://doi.org/10.1186/1750-9378-3-3

Madden T. BLAST Help Manual Overview: In: BLAST® Help [Internet]. Bethesda (USA): National Center for Biotechnology Information; 2008.

Manos MM. The detection of genital human papillomavirus infection using polymerase chain reaction-replica. JAMA. 1991 Jun 5; 265(21): 2809. https://doi.org/10.1001/jama.1991.03460210055024

Mayaud P, Gill DK, Weiss HA, Uledi E, Kopwe L, Todd J, ka-Gina G, Grosskurth H, Hayes RJ, Mabey DC, et al. The interrelation of HIV, cervical human papillomavirus, and neoplasia among antenatal clinic attenders in Tanzania. Sex Transm Infect. 2001 Aug 1;77(4):248–254. https://doi.org/10.1136/sti.77.4.248

Mbulawa ZZ, Coetzee D, Marais DJ, Kamupira M, Zwane E, Allan B, Constant D, Moodley JR, Hoffman M, Williamson AL. Genital human papillomavirus prevalence and human papillomavirus concordance in heterosexual couples are positively associated with human immunodeficiency virus coinfection. J Infect Dis. 2009 May 15;199(10):1514–1524.

https://doi.org/10.1086/598220

Menon S, Wusiman A, Boily MC, Karisa M, Mabey H, Luchters S, Forland F, Rossi R, Callens S, vanden Broeck D. Epidemiology of HPV genotypes among HIV positive women in Kenya: a systematic review and meta-analysis. PLoS One. 2016 Oct 20;11(10):e0163965. https://doi.org/10.1371/journal.pone.0163965

Montoya Guarín CJ, Moreno Fernández ME, Rugeles López MT. Reacciones y alteraciones del sistema inmune durante la infección por el VIH-1. Infectio. 2006;10(4):250–265.

Montoya-Fuentes H, Suárez Rincón AE, Ramírez-Muñoz MP, Arévalo-Lagunas I, Morán Moguel MC, Gallegos Arreloa MP, Flores-Martínez SE, Rosales Quintana S, Sánchez Corona J. Detección de papilomavirus humano tipos 16, 18, 35 y 58 en cáncer cervicouterino y lesiones escamosas intraepiteliales de alto grado en el occidente de México: correlación clínico-molecular. Ginecol Obstet Mex. 2001 Apr;69(4):137–142.

Muñoz N, Bosch FX, de Sanjose S, Shah KV. The role of HPV in the etiology of cervical cancer. Mutat Res Fundam Mol Mech Mutagen. 1994 Mar;350(1-2):293–301. https://doi.org/10.1016/0140-6736(97)09028-4

Nayar R, Willbur DC. The Pap Test and Bethesda 2014. “The reports of my demise have been greatly exaggerated.” (after a quotation from Mark Twain). Acta Cytol. 2015;59(2):121–132. https://doi.org/10.1159/000381842

Nyasaou YT, Gbeasor-Komalvi FA, Eklan A, Issa SAR, Dossim S, Kolou M, Yambio BM, Prince-David M, Salou M, Ekouevi DK, et al. Prevalence and distribution of Human Papillomavirus (HPV) genotypes among HPV infected women in Lomé, Togo. PLoS One. 2019 Feb 27;14(2):e0212516. https://doi.org/10.1371/journal.pone.0212516

Oliveira GR, Siqueira JD, Finger-Jardim F, Vieira VC, Silva RL, Gonçalves CV, Soares EA, Martinez AMB, Soares MA. Characterisation of complete high- and low-risk human papillomavirus genomes isolated from cervical specimens in southern Brazil. Mem Inst Oswaldo Cruz. 2017 Oct;112(10):728–731.

https://doi.org/10.1016/j.ijc.20121

https://doi.org/10.1002/1097-2156(20010210)91:3<412::AID-IJC1071>3.0.CO;2-M

Lillo FB, Ferrari D, Veglia F, Origoni M, Grasso MA, Lodini S, Mastroirilli E, Taccagni G, Lazzarin A, Uberti-Foppa C. Human papillomavirus infection and associated cervical disease in human immunodeficiency virus-infected women: effect of highly active antiretroviral therapy. J Infect Dis. 2001 Sep;184(5):547–551. https://doi.org/10.1086/328586

López Rivera MG, Flores MOM, Villalba Magdaleno JDA, Sánchez Monroy V. Prevalence of human papillomavirus in women from Mexico City. Infect Dis Obstet Gynecol. 2012;2012:1–4.

https://doi.org/10.1155/2012/384758

Ortega-Cervantes L, Aguilar-Lemarroy A, Rojas-Garcia AE, Barrón-Vivanco BS, Vallejo-Ruiz V, León DC, Hernández YY, Jáuregui-Martínez A, Medina-Díaz IM. Human papillomavirus genotypes in women from Nayarat, Mexico, with squamous intraepithelial lesions and cervical cancer. Int J Health Sci (Qassim). 2016 Jul;10(3):327–338. https://doi.org/10.12816/0048727
Genetic variants of human papillomavirus in Mexico

Ortiz AP, Engels EA, Nogueiras-González GM, Colón-López V, Soto-Salgado M, Vargas A, Machin M, Shiel MS. Disparities in human papillomavirus-related cancer incidence and survival among human immunodeficiency virus-infected Hispanics living in the United States. Cancer. 2018 Dec;124(23):4520–4528. https://doi.org/10.1002/cncr.31702

Palefsky J. Human papillomavirus-related disease in people with HIV. Curr Opin HIV AIDS. 2009 Jan;4(1):52–56. https://doi.org/10.1097/COH.0b013e32831a7246

Peralta-Rodriguez R, Romero-Morelos P, Villegas-Ruiz V, Mendoza-Rodriguez M, Taniguchi-Ponciano K, González-Yebra B, Marrero-Rodríguez D, Salcedo M. Prevalence of human papillomavirus in the cervical epithelium of Mexican women: meta-analysis. Infect Agent Cancer. 2012 Dec;7(1):34. https://doi.org/10.1186/1750-9387-7-34

Qu W, Jiang G, Cruz Y, Chang CJ, Ho GY, Klein RS, Burd RD. PCR detection of human papillomavirus: comparison between MY09/MY11 and GP5+/GP6+ primer systems. J Clin Microbiol. 1997 Jun;35(6):1304–1310. https://doi.org/10.1128/icmp.35.6.1304-1310.1997

Rodrigues LLS, Morgado MG, Sahasarabduhche VV, de Paula VS, Oliveira NS, Chavez-Juán E, da Silva DM, Kast WM, Nicol AF, Pilotto JH. Cervico-vaginal self-collection in HIV-infected and uninfected women from Tapajós region, Amazon, Brazil: high acceptability, hrHPV diversity and risk factors. Gynecol Oncol. 2018 Oct;151(1):102–110. https://doi.org/10.1016/j.ygyno.2018.08.004

Roy A, Yang J, Zhang Y. COFACTOR: an accurate comparative algorithm for structure-based protein function annotation. Nucleic Acids Res. 2012 Jul 01;40(W1):W471–W477. https://doi.org/10.1093/nar/gks372

Sabin CA, Phillips AN. Should HIV therapy be started at a CD4 cell count above 350 cells/μl in asymptomatic HIV-1-infected patients? Curr Opin Infect Dis. 2009 Apr;22(2):191–197. https://doi.org/10.1097/QCO.0b013e328236cd34

Sahasrarabduhche VV, Mwanahamuntu MH, Vermund SH, Huh WK, Lyon MD, Stringer JSA, Parham GP. Prevalence and distribution of HPV genotypes among HIV-infected women in Zambia. Br J Cancer. 2007 May;96(9):1480–1483. https://doi.org/10.1038/sj.bjc.6603737

Salcedo M, Pina-Sánchez P, Vallejo-Ruiz V, Monroy-García A, Aguilar-Lemarroy A, Cortés-Gutierrez EI, Santos-Lopez G, Montoya-Fuentes H, Grijalva R, Madrid-Marina V, et al. Human papillomavirus genotypes among females in Mexico: a study from the Mexican institute for social security. Asian Pac J Cancer Prev. 2015 Jan 06;15(23):10061–10066. https://doi.org/10.7314/APJCP.2014.15.23.10061

Singh DK, Anastos K, Hoover DR, Burd RK, Shi Q, Ngendahayo L, Mutimura E, Cajigas A, Bigirimani V, Cai X, et al. Human papillomavirus infection and cervical cytology in HIV-infected and HIV-uninfected Rwandan women. J Infect Dis. 2009 Jun 15;199(12):1851–1861. https://doi.org/10.1086/599123

Sopracordevole F, Campagnutta E, Parin A, Vaccher E, Volpe R, Scarabelli C. Squamous intraepithelial cervical lesions in human immunodeficiency virus-seropositive women. J Reprod Med. 1996 Aug;41(8):586–590.

Videla S, Darwich L, Cañadas MP, Paredes R, Tarrats A, Castella E, Llatjos M, Bofill M, Cлотet B, Sirera G; HIV-HPV Study Group. Epidemiological data of different human papillomavirus genotypes in cervical specimens of HIV-1-infected women without history of cervical pathology. J Acquir Immune Defic Syndr. 2009 Feb;50(2):168–175. https://doi.org/10.1097/QAI.0b013e3181938e63

Vyanakondadera J, Wambua S, Irungu E, Mandaliya K, Temmerman M, Ryan C, Mohamed Y, Vanden Broeck D, Verhelst R, Chersich MF, et al. Type-specific human papillomavirus prevalence, incident cases, persistence, and associated pregnancy outcomes among HIV-infected women in Kenya. Sex Transm Dis. 2019 Aug;46(8):532–539. https://doi.org/10.1097/OLQ.00000000000001029

WHO. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach – 2010 revision. Geneva (Switzerland): World Health Organization; 2010 [cited 2021 Jul 01]. Available from: https://apps.who.int/iris/handle/10665/44379

WHO. Guidelines for using HIV testing technologies in surveillance: selection, evaluation and implementation – 2009 update. Geneva (Switzerland): World Health Organization; 2009.

WHO. Human papillomavirus (HPV) and cervical cancer [Internet]. Geneva (Switzerland): World Health Organization; 2020 Nov 11 [cited 2021 Jul 01]. Available from: https://www.who.int/news-room/fact-sheets/detail/human-papillomavirus-(hpv)-and-cervical-cancer

Wu S, Zhang Y. LOMETS: a local meta-threading-server for protein structure prediction. Nucleic Acids Res. 2007;35(10):3375–3382. https://doi.org/10.1093/nar/gkm251

Xu J, Tan I, Wang T, Cui F, Ding X, Wan Q, Deng D, Chen Z. Genetic variability of human papillomavirus type 51 E6, E7, L1 and L2 genes in Southwest China. Gene. 2019 Mar;46(8):3375–3382. https://doi.org/10.1093/nar/gks251

Yamada R, Sagasawa T, Kirumbi IJ, Kingoro A, Karanja DK, Kiptoo M, Mwanahamuntu H. Type-specific human papillomavirus infection and cervical abnormalities in Nairobi, Kenya, an area with a high prevalence of human immunodeficiency virus infection. J Med Virol. 2008 May;80(5):847–855. https://doi.org/10.1002/jmv.21170

Yang J, Zhang Y. I-TASSER server: new development for protein structure and function predictions. Nucleic Acids Res. 2015 Jul 01;43(W1):W174–W181. https://doi.org/10.1093/nar/gkv342